Vaxxas, Merck deal

Vaxxas granted Merck exclusive, worldwide rights to develop and commercialize an undisclosed Merck vaccine using Vaxxas' needle-free Nanopatch vaccine delivery technology. Merck also has an option to license the technology for use with two additional undisclosed vaccine candidates. Vaxxas will receive an upfront payment and research funding. Vaxxas is eligible for milestones, plus royalties. The companies declined to disclose details. ...